Abstract #4264

Determination of the fate of intravenously administered Gd(III)DOTA-DSPE-based liposomal contrast agent in a mouse model

ERIC A TANIFUM^1,2, Conelius Ngwa³, Laxman Devkota³, Andrew A Badachhape³, Ketan B Ghaghada^3,4, Prajwal Bhandari², Igor Stupin⁴, Mayank Srivastava⁴, and Ananth V Annapragada^1,2

¹Pediatric Radiology, Texas Children's Hospital, Houston, TX, United States, ²Radiology, Baylor College of Medicine, Houston, TX, United States, ³Baylor College of Medicine, Houston, TX, United States, ⁴Texas Children's Hospital, Houston, TX, United States

Small molecule conventional gadolinium (Gd) present some safety concerns including nephrogenic systemic fibrosis (NSF) and brain accumulation. Nanoparticle-based gadolinium (Gd) agents may alleviate these concerns by streamlining the clearance pathways of the agent.Liposomal Gd(III)DOTA-DSPE conjugate exhibit high relaxivity at clinically-relevant MR field strength, and enables molecular MR imaging mice. We report herein an investigation on the pharmacokinetics, bio-distribution and clearance of a liposomal-Gd agent in mice over a period of 28 days by T1-weighted MR imaging and ICP-MS analyses. Results show no significant skin or brain accumulation, suggesting NSF and brain accumulation concerns may be unlikely with such agent.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.